Category Archives: Hematopoiesis

Hematopoiesis News is an online publication and email newsletter that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.
Subscribe
Hematopoiesis News is a weekly newsletter in which we curate the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.

Decline in IGF1 in the Bone Marrow Microenvironment Initiates Hematopoietic Stem Cell Aging

Scientists discover that hallmarks of aging in HSCs and hematopoiesis begin to accumulate by middle age and that the bone marrow microenvironment at middle age induced and was indispensable for hematopoietic aging.
[Cell Stem Cell]
Young, K., Eudy, E., Bell, R., Loberg, M. A., Stearns, T., Sharma, D., Velten, L., Haas, S., Filippi, M.-D., & Trowbridge, J. J. (2021). Decline in IGF1 in the bone marrow microenvironment initiates hematopoietic stem cell aging. Cell Stem Cell. https://doi.org/10.1016/j.stem.2021.03.017 Cite
AbstractFull Article
Bookmark

No account yet? Register

0
Share

P300/CBP Inhibition Sensitizes Mantle Cell Lymphoma to PI3Kδ Inhibitor Idelalisib

Scientists report that a p300/CBP inhibitor, A-485, could overcome resistance to idelalisib in mantle cell lymphoma cells in vitro and in vivo.
[Acta Pharmacologica Sinica]
Zhou, X., Li, X., Liao, L., Han, J., Huang, J., Li, J., Tao, H., Fan, S., Chen, Z., Li, Q., Chen, S., Ding, H., Yang, Y., Zhou, B., Jiang, H., Chen, K., Zhang, Y., Huang, C., & Luo, C. (2021). P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. Acta Pharmacologica Sinica, 1–13. https://doi.org/10.1038/s41401-021-00643-2 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Targeting AXL Kinase Sensitizes Leukemic Stem and Progenitor Cells to Venetoclax Treatment in Acute Myeloid Leukemia

Researchers demonstrated that a key GAS6/AXL axis was highly activated in acute myeloid leukemia patient cells, particularly in stem/progenitor cells.
[Blood]
Niu, X., Rothe, K., Chen, M., Grasedieck, S., Li, R., Nam, S.-E., Zhang, X., Novakovskiy, G., Ahn, Y.-H., Maksakova, I. A., Lai, S., Zhang, H., Yan, J., Liu, H., Zhao, Y., Wu, D., Ge, Y., Wasserman, W., Rouhi, A., … Jiang, X. (2021). Targeting AXL Kinase Sensitizes Leukemic Stem and Progenitor Cells to Venetoclax Treatment in Acute Myeloid Leukemia. Blood, blood.2020007651. https://doi.org/10.1182/blood.2020007651 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Procalcitonin and C-Reactive Protein Predict Infection in Hematopoietic Stem Cell Transplantation Patients

Scientists evaluated procalcitonin and C-reactive proteinas markers of infection in hematopoietic stem cell transplantation patients.
[Leukemia Research]
Li, S., Gu, J., Nan, W., Zhang, N., Qin, L., Su, M., & Jia, M. (2021). Procalcitonin and C-reactive protein predict infection in hematopoietic stem cell transplantation patients. Leukemia Research, 105, 106574. https://doi.org/10.1016/j.leukres.2021.106574 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma

Arcellx announced that the FDA has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma. ACLX-001 is the first clinical application of the company’s ARC-SparX platform of controllable and adaptable cell therapies.
[Arcellx]
josh@comocreative.com. (2021, April 6). Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma. Arcellx. https://arcellx.com/arcellx-announces-fda-clearance-of-ind-application-for-aclx-001-a-controllable-cell-therapy-utilizing-the-companys-arc-sparx-platform-for-the-treatment-of-multiple-myeloma/ Cite
Press Release
Bookmark

No account yet? Register

0
Share

Deregulation of Enhancer Structure, Function, and Dynamics in Acute Lymphoblastic Leukemia

Investigators present recent discoveries of the role of enhancer dynamics in mouse and human lymphoid development, and discuss how genetic and epigenetic alterations of enhancer function can promote leukemogenesis, and potential strategies for targeting the enhancer machinery in the treatment of acute lymphoblastic leukemia.
[Trends in Immunology]
Belver, L., Albero, R., & Ferrando, A. A. (2021). Deregulation of enhancer structure, function, and dynamics in acute lymphoblastic leukemia. Trends in Immunology, 0(0). https://doi.org/10.1016/j.it.2021.03.005 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas

Celularity, Inc. announced FDA has granted Orphan Drug Designation to the company’s non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, for the treatment of patients with malignant gliomas.
[Celularity, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Minor Intron Retention Drives Clonal Hematopoietic Disorders and Diverse Cancer Predisposition

The authors identified that impaired minor intron excision via ZRSR2 loss enhanced hematopoietic stem cell self-renewal.
[Nature Genetics]
Inoue, D., Polaski, J. T., Taylor, J., Castel, P., Chen, S., Kobayashi, S., Hogg, S. J., Hayashi, Y., Pineda, J. M. B., El Marabti, E., Erickson, C., Knorr, K., Fukumoto, M., Yamazaki, H., Tanaka, A., Fukui, C., Lu, S. X., Durham, B. H., Liu, B., … Abdel-Wahab, O. (2021). Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nature Genetics, 1–12. https://doi.org/10.1038/s41588-021-00828-9 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Stem Cell Concepts in Myelodysplastic Syndromes: Lessons and Challenges

The clinical importance of myelodysplastic syndromes (MDS) stem cells has been highlighted through the demonstration of selective persistence of MDS stem cells in patients at complete remission in response to therapy.
[Journal of Internal Medicine]
Woll, P. S., & Jacobsen, S. E. W. (n.d.). Stem cell concepts in myelodysplastic syndromes: lessons and challenges. Journal of Internal Medicine, n/a(n/a). https://doi.org/https://doi.org/10.1111/joim.13283 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Anti-CLL1 Chimeric Antigen Receptor T Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia

Scientists tested the safety and efficacy of chimeric antigen receptor T cell therapy in refractory/relapsed acute myeloid leukemia .
[Clinical Cancer Research]
Zhang, H., Wang, P., Li, Z., He, Y., Gan, W., & Jiang, H. (2021). Anti-CLL1 chimeric antigen receptor T cell therapy in children with relapsed/refractory acute myeloid leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-4543 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial to reduce prescribed radiation in children and adolescents with classical HL.
[Journal of Clinical Oncology]
Metzger, M. L., Link, M. P., Billett, A. L., Flerlage, J., Lucas, J. T., Mandrell, B. N., Ehrhardt, M. J., Bhakta, N., Yock, T. I., Friedmann, A. M., de Alarcon, P., Luna-Fineman, S., Larsen, E., Kaste, S. C., Shulkin, B., Lu, Z., Li, C., Hiniker, S. M., Donaldson, S. S., … Krasin, M. J. (2021). Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. Journal of Clinical Oncology, JCO.20.03286. https://doi.org/10.1200/JCO.20.03286 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share